Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Second-line sacituzumab govitecan improves survival in metastatic TNBC Next Article
Prognostic value of tumour infiltrating lymphocytes in young TNBC patients »
« Second-line sacituzumab govitecan improves survival in metastatic TNBC Next Article
Prognostic value of tumour infiltrating lymphocytes in young TNBC patients »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles

November 25, 2020
Second-line sacituzumab govitecan improves survival in metastatic TNBC

November 25, 2020
Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy